New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:49 EDTHPTXHyperion Therapeutics completes acquisition of Andromeda Biotech
Hyperion Therapeutics announced that it has completed its previously announced acquisition of Andromeda Biotech. The acquisition broadens Hyperion's pipeline to include DiaPep277, a potentially first-in-class immunotherapy for new onset Type 1 diabetes that is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds Orphan Drug designation in the U.S.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:43 EDTHPTXHyperion Therapeutics management to meet with Needham
Meetings to be held in Detroit/Chicago on March 31 and in Chicago on April 1 hosted by Needham.
March 25, 2015
11:01 EDTHPTXHyperion Therapeutics price target raised to $51 from $40 at Brean Capital
Subscribe for More Information
March 23, 2015
11:16 EDTHPTXHyperion Therapeutics price target raised to $52 from $36 at Wedbush
Wedbush raised Hyperion's price target to $52 ahead of the hepatic encephalopathy Phase III trial of Ravicti and the likelihood of success. Shares are Outperform rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use